MA60154A1 - Inhibiteurs de line-1 pour traiter une maladie - Google Patents

Inhibiteurs de line-1 pour traiter une maladie

Info

Publication number
MA60154A1
MA60154A1 MA60154A MA60154A MA60154A1 MA 60154 A1 MA60154 A1 MA 60154A1 MA 60154 A MA60154 A MA 60154A MA 60154 A MA60154 A MA 60154A MA 60154 A1 MA60154 A1 MA 60154A1
Authority
MA
Morocco
Prior art keywords
inhibitors
line
treat disease
subject
methods
Prior art date
Application number
MA60154A
Other languages
English (en)
Other versions
MA60154B1 (fr
Inventor
Claudio Sturino
Malay Doshi
Eckard Weber
Michael G Cordingley
Original Assignee
Transposon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposon Therapeutics Inc filed Critical Transposon Therapeutics Inc
Publication of MA60154A1 publication Critical patent/MA60154A1/fr
Publication of MA60154B1 publication Critical patent/MA60154B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des procédés de traitement ou de prévention d'une maladie, d'un trouble, ou d'un état chez un sujet en ayant besoin, les procédés comprenant l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé de formule i: ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, ou un tautomère de ceux-ci, dans laquelle r1, r2 et b sont tels que définis dans la description.
MA60154A 2020-09-23 2021-09-23 Inhibiteurs de line-1 pour traiter une maladie MA60154B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082185P 2020-09-23 2020-09-23
US202163161055P 2021-03-15 2021-03-15
PCT/US2021/051716 WO2022066880A1 (fr) 2020-09-23 2021-09-23 Inhibiteurs de line-1 pour traiter une maladie

Publications (2)

Publication Number Publication Date
MA60154A1 true MA60154A1 (fr) 2023-06-28
MA60154B1 MA60154B1 (fr) 2024-10-31

Family

ID=80845827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA60154A MA60154B1 (fr) 2020-09-23 2021-09-23 Inhibiteurs de line-1 pour traiter une maladie

Country Status (14)

Country Link
US (1) US20230414616A1 (fr)
EP (1) EP4216962A4 (fr)
JP (1) JP7858661B2 (fr)
KR (1) KR20230107543A (fr)
AU (1) AU2021347247A1 (fr)
CA (1) CA3193512A1 (fr)
CL (1) CL2023000857A1 (fr)
DO (1) DOP2023000060A (fr)
IL (1) IL301564A (fr)
MA (1) MA60154B1 (fr)
MX (1) MX2023003332A (fr)
PH (1) PH12023550780A1 (fr)
UA (1) UA130470C2 (fr)
WO (1) WO2022066880A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066835A1 (fr) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Analogues de n-(2-(2,6-dioxopipéridine-3-yl)-1,3-dioxoisoindoline-5-yl)arylsulfonamide substitués en tant que modulateurs de la protéine cereblon
AU2022237405A1 (en) * 2021-03-15 2023-11-02 Transposon Therapeutics, Inc. Line-1 inhibitors to treat cns and systemic diseases
AU2022283915A1 (en) * 2021-06-04 2024-01-18 Transposon Therapeutics, Inc. Line-1 inhibitors as cognitive enhancers
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法
WO2023192491A2 (fr) * 2022-03-30 2023-10-05 Transposon Therapeutics, Inc. Inhibiteurs nucléosidiques de line-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117986A (en) * 1998-06-10 2000-09-12 Intergen Company, L.P. Pyrimidines linked to a quencher
WO2012048113A2 (fr) * 2010-10-07 2012-04-12 The General Hospital Corporation Biomarqueurs de cancer
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.

Also Published As

Publication number Publication date
US20230414616A1 (en) 2023-12-28
CA3193512A1 (fr) 2022-03-31
AU2021347247A9 (en) 2024-09-05
EP4216962A4 (fr) 2024-11-20
KR20230107543A (ko) 2023-07-17
EP4216962A1 (fr) 2023-08-02
JP7858661B2 (ja) 2026-05-14
DOP2023000060A (es) 2023-09-29
CL2023000857A1 (es) 2023-11-10
MA60154B1 (fr) 2024-10-31
PH12023550780A1 (en) 2023-06-14
MX2023003332A (es) 2023-06-16
WO2022066880A1 (fr) 2022-03-31
TW202228723A (zh) 2022-08-01
IL301564A (en) 2023-05-01
JP2023549979A (ja) 2023-11-29
AU2021347247A1 (en) 2023-06-08
UA130470C2 (uk) 2026-02-25

Similar Documents

Publication Publication Date Title
MA63032B1 (fr) Composés contenant du nitrile pour utilisation comme médicaments
MA57933B1 (fr) Composés hautement actifs contre la covid-19
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
MA57539B1 (fr) Inhibiteurs à petites molécules de mutant de kras g12c
US9326972B2 (en) Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA58993A1 (fr) Antagoniste du récepteur crf1 pour le traitement de l'hyperplasie surrénale congénitale
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
PH12021500049A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
MA63501B1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA30073B1 (fr) Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine
MA51837B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA43468B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA29326B1 (fr) Combinaison de composes organiques
MA31335B1 (fr) Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA60154B1 (fr) Inhibiteurs de line-1 pour traiter une maladie
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
JP2021522247A5 (fr)
MA30704B1 (fr) Compositions therapeutiques